What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Elevated Lipoprotein(a) (n=24940). Intervention: Statins vs. Placebo or active comparator. Primary outcome: Mean difference of absolute change (MDAC) in Lp(a) concentration (MDAC 0.22 mg/dL).

What does this research mean for the field?

Statin therapy does not significantly affect Lipoprotein(a) levels, indicating that statin administration does not alter the cardiovascular risk associated with elevated Lipoprotein(a). Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine whether statin therapy significantly lowers serum lipoprotein(a) concentrations in patients.

January 16, 2025Reviews in Cardiovascular MedicineOpen Access

Statins—Their Effect on Lipoprotein(a) Levels

View Full Paper

Ask AI

Bookmark

Key result

Statin therapy shows no significant effect on Lp(a) levels.

MDAC 0.22 mg/dL
n=24,940

Why the study?

Statins successfully lower LDL-C in patients with elevated Lp(a), but their effectiveness in reducing Lp(a) levels is uncertain.

Does statin therapy reduce Lipoprotein(a) concentration in patients compared to placebo or active comparator?

Population

13,264 participants in study arms and 11,676 in control arms across 43 studies

Comparison

Statin therapy vs placebo or comparator arm

Design

Systematic review and meta-analysis of randomised controlled studies

Authors

MGMarcin Mateusz GranatMedical University of Warsaw

Discussion

Member takes

Implication

Statin therapy will not modify Lp(a)-associated cardiovascular risk; confirms dedicated Lp(a)-lowering agents are required.

Key Points

To determine whether statin therapy significantly lowers serum lipoprotein(a) concentrations in patients.
Systematically searched PubMed, Embase, Cochrane Library, ScienceDirect, Scopus, Springer Link, and Oxford Academic from May 1 to August 10, 2024.
Identified and included 43 randomized controlled trials with a placebo or comparator arm, comprising 13,264 participants in statin arms and 11,676 participants in control arms.
Assessed trial bias using the revised Cochrane risk-of-bias tool for randomized trials and performed analyses using SPSS Statistics version 29.
Statin therapy produced a clinically non-significant mean difference of absolute change in lipoprotein(a) concentration of 0.22 mg/dL across all 43 trials.
Evaluation of publication bias via Egger's regression-based test showed no significant bias across the included studies (p = 0.404).

Study Design

Type

Meta-Analysis (n=24,940)

Structured PICO

Does statin therapy reduce Lipoprotein(a) concentration in patients compared to placebo or active comparator?

Population

24,940 participants (13,264 in study arms and 11,676 in control arms) from 43 randomized controlled trials and studies with a placebo/comparator arm. Overall mean age in adult studies 60 years, 61% male.

Intervention

Statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin) administered for 3 weeks to 3 years

Comparator

Placebo or active comparator

Outcome

Mean difference of absolute change (MDAC) in Lipoprotein(a) concentrationsurrogate

Main Result

Effect estimate: MDAC 0.22 mg/dL

Statin therapy does not significantly affect Lipoprotein(a) levels, suggesting that statin administration will not alter Lp(a)-associated cardiovascular risk.

Limitations

High risk of bias in studies reporting a significant increase in Lp(a)
Small diversity of baseline Lp(a) among participants, mostly within the range of 10-35 mg/dL
Lack of stratification of results based on sex
Small number of participants in studies showing a significant reduction in Lp(a)
Diversity of baseline Lp(a) among participants was relatively small (10-35 mg/dL in 22 out of 30 studies)
Published studies generally lack consideration of Lp(a) genetic regulators

Cite This Study

Marcin Mateusz Granat (2025) conducted a meta-analysis in Elevated Lipoprotein(a) (n=24,940). Statins vs. Placebo or active comparator was evaluated on Mean difference of absolute change (MDAC) in Lp(a) concentration (MDAC 0.22 mg/dL). Statin therapy does not significantly affect Lipoprotein(a) levels, with a mean difference of absolute change of 0.22 mg/dL across 43 studies.

synapsesocial.com/papers/6a17d296cf49e78c48b47d9d https://doi.org/10.31083/rcm26162

Topics

Statin therapy Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

January 16, 2025Reviews in Cardiovascular MedicineOpen Access

Statins—Their Effect on Lipoprotein(a) Levels

View Full Paper

Ask AI

Bookmark

Key result

Statin therapy shows no significant effect on Lp(a) levels.

MDAC 0.22 mg/dL
n=24,940

Why the study?

Statins successfully lower LDL-C in patients with elevated Lp(a), but their effectiveness in reducing Lp(a) levels is uncertain.

Does statin therapy reduce Lipoprotein(a) concentration in patients compared to placebo or active comparator?

Population

13,264 participants in study arms and 11,676 in control arms across 43 studies

Comparison

Statin therapy vs placebo or comparator arm

Design

Systematic review and meta-analysis of randomised controlled studies

Authors

MGMarcin Mateusz GranatMedical University of Warsaw

Discussion

Member takes

Implication

Statin therapy will not modify Lp(a)-associated cardiovascular risk; confirms dedicated Lp(a)-lowering agents are required.

Key Points

To determine whether statin therapy significantly lowers serum lipoprotein(a) concentrations in patients.
Systematically searched PubMed, Embase, Cochrane Library, ScienceDirect, Scopus, Springer Link, and Oxford Academic from May 1 to August 10, 2024.
Identified and included 43 randomized controlled trials with a placebo or comparator arm, comprising 13,264 participants in statin arms and 11,676 participants in control arms.
Assessed trial bias using the revised Cochrane risk-of-bias tool for randomized trials and performed analyses using SPSS Statistics version 29.
Statin therapy produced a clinically non-significant mean difference of absolute change in lipoprotein(a) concentration of 0.22 mg/dL across all 43 trials.
Evaluation of publication bias via Egger's regression-based test showed no significant bias across the included studies (p = 0.404).

Study Design

Type

Meta-Analysis (n=24,940)

Structured PICO

Does statin therapy reduce Lipoprotein(a) concentration in patients compared to placebo or active comparator?

Population

Intervention

Statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin) administered for 3 weeks to 3 years

Comparator

Placebo or active comparator

Outcome

Mean difference of absolute change (MDAC) in Lipoprotein(a) concentrationsurrogate

Main Result

Effect estimate: MDAC 0.22 mg/dL

Statin therapy does not significantly affect Lipoprotein(a) levels, suggesting that statin administration will not alter Lp(a)-associated cardiovascular risk.

Limitations

High risk of bias in studies reporting a significant increase in Lp(a)
Small diversity of baseline Lp(a) among participants, mostly within the range of 10-35 mg/dL
Lack of stratification of results based on sex
Small number of participants in studies showing a significant reduction in Lp(a)
Diversity of baseline Lp(a) among participants was relatively small (10-35 mg/dL in 22 out of 30 studies)
Published studies generally lack consideration of Lp(a) genetic regulators

Cite This Study

synapsesocial.com/papers/6a17d296cf49e78c48b47d9d https://doi.org/10.31083/rcm26162

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Statin therapy Cardiovascular prevention

View Full Paper

Ask AI

Bookmark